McKesson Corporation (NYSE: MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on ...

McKesson Corporation ( (MCK) ) has released its Q2 earnings. Here is a breakdown of the information McKesson Corporation presented to its ...

McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical ...

Highlights:,Baird upgraded McKesson Corporation’s stock from Neutral to Outperform, raising its price target to $688 from $531.,McKesson's strong performance in the U.S. Pharmaceutical Distribution ...

McKesson's earnings for its fiscal 2025 second quarter exceeded expectations, despite special charges that cut into net ...

U.S. stocks are mixed on Thursday ahead of the Federal Reserve’s announcement coming in the afternoon about what it will do ...

Drug distributor McKesson Corp raised its annual profit forecast on Wednesday, driven by increased sales in its U.S.

U.S. stocks are ticking higher ahead of the Federal Reserve’s announcement coming later in the afternoon about what it will ...

McKesson (MCK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Allen Lutz ...

McKesson (MCK) stock traded higher as Baird upgraded the company to outperform citing its Core Ventures deal and its strong Q2 FY25 earnings. Read more here.

McKesson MCK reported better-than-expected second-quarter financial results on Wednesday. McKesson reported quarterly earnings of $7.07 per share which beat the analyst consensus estimate of $6.88 per ...

U.S. stocks are mixed ahead of the Federal Reserve’s announcement coming later in the afternoon about what it will do with ...